Passage Bio, a preclinical biotech developing gene therapies for rare CNS disorders, increased the proposed share offering for its upcoming IPO on Thursday. The Philadelphia, PA-based company now ...

Passage Bio, a preclinical biotech developing gene therapies for rare CNS disorders, announced terms for its IPO on Tuesday. The Philadelphia, PA-based company plans to raise $126 million by ...

Passage Bio, an early stage biotech developing therapies for monogenic CNS disorders, filed on Monday with the SEC to raise up to $125 million in an initial public offering.The Philadelphia, PA ...

Passage Bio, a preclinical biotech developing gene therapies for rare CNS disorders, raised $216 million by offering an upsized 12 million shares at $18, the high end of the range of $16 to $18.

Passage Bio, Inc. (NASDAQ:PASG) is a genetic medicine company with a strong development pipeline. ... The company had issued its IPO at $18 and it is currently trading close to $16, ...

Passage Bio Inc. shares soared 19% in their ... from these life-threatening disorders," the company said in its IPO filing ... stock quotes reflect trades reported through Nasdaq ...

Passage Bio (NASDAQ:PASG) had its IPO in 2019 at over $20.00 per share and then hit a peak at $36.07 in June 2021. This gene-therapy biotech closed on February 24, 2023, at $1.17 per share.

Passage Bio (NASDAQ:PASG) intends to raise $125 million in an IPO.This is according to an S-1 registration statement filed with the SEC. This biotech has a lead gene therapy program that is ...

Shares of Passage Bio were up almost 20% at 2:19 p.m. EST Friday. Image source: Getty Images. The company, which was spun out of the gene therapy program at the University of Pennsylvania, has ...

The biggest drop among the companies trading below their IPO price is by Passage Bio (NASDAQ: PASG), which went public in 2020 at $18 per share and closed Dec. 23 at $1.28.

(RTTNews) - Genetic Medicines Company Passage Bio (PASG) announced the pricing of initial public offering of 12 million common shares at $18.00 per share, the high end of the expected range of $16 ...